{"protocolSection": {"identificationModule": {"nctId": "NCT01337674", "orgStudyIdInfo": {"id": "4618-010"}, "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "Co-Administration of MK-4618 With Antihypertensive Agents (MK-4618-010)", "officialTitle": "A Study to Evaluate the Co-Administration of MK-4618 With Antihypertensive Agents"}, "statusModule": {"statusVerifiedDate": "2018-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-04-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2011-11-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-11-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-04-15", "studyFirstSubmitQcDate": "2011-04-15", "studyFirstPostDateStruct": {"date": "2011-04-19", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-10-30", "resultsFirstSubmitQcDate": "2015-12-22", "resultsFirstPostDateStruct": {"date": "2016-02-02", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-12-03", "lastUpdatePostDateStruct": {"date": "2018-12-24", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study will evaluate the safety and tolerability of MK-4618 when coadministered with antihypertensive agents and will evaluate changes in blood pressure following co-administration of MK-4618 with a beta blocker and a vasodilator. The primary hypothesis of the study is that MK-4618 does not result in a clinically meaningful change in systolic blood pressure relative to placebo when co-administered with a beta-blocker or with amlodipine."}, "conditionsModule": {"conditions": ["Hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 26, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Panel A: MK-4618 + Met \u2192 PBO + Met", "type": "EXPERIMENTAL", "description": "Once daily oral dose of MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 1 followed by once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of metoprolol (Met) for the duration of the study. A 2-week washout period follows Period 1.", "interventionNames": ["Drug: MK-4618", "Drug: Placebo for MK-4618", "Drug: Metoprolol"]}, {"label": "Panel A: PBO + Met \u2192 MK-4618 + Met", "type": "EXPERIMENTAL", "description": "Once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 1 followed by MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of metoprolol (Met) for the duration of the study. A 2-week washout period follows Period 1.", "interventionNames": ["Drug: MK-4618", "Drug: Placebo for MK-4618", "Drug: Metoprolol"]}, {"label": "Panel B: MK-4618 + Amlo \u2192 PBO + Amlo", "type": "EXPERIMENTAL", "description": "Once daily oral dose of MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 1 followed by once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of amlodipine (Amlo) for the duration of the study. A 2-week washout period follows Period 1.", "interventionNames": ["Drug: MK-4618", "Drug: Placebo for MK-4618", "Drug: Amlodipine"]}, {"label": "Panel B: PBO + Amlo \u2192 MK-4618 + Amlo", "type": "EXPERIMENTAL", "description": "Once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 1 followed by MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of amlodipine (Amlo) for the duration of the study. A 2-week washout period follows Period 1.", "interventionNames": ["Drug: MK-4618", "Drug: Placebo for MK-4618", "Drug: Amlodipine"]}], "interventions": [{"type": "DRUG", "name": "MK-4618", "description": "Once daily oral dose of MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7", "armGroupLabels": ["Panel A: MK-4618 + Met \u2192 PBO + Met", "Panel A: PBO + Met \u2192 MK-4618 + Met", "Panel B: MK-4618 + Amlo \u2192 PBO + Amlo", "Panel B: PBO + Amlo \u2192 MK-4618 + Amlo"]}, {"type": "DRUG", "name": "Placebo for MK-4618", "description": "Once daily oral dose of placebo for MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7", "armGroupLabels": ["Panel A: MK-4618 + Met \u2192 PBO + Met", "Panel A: PBO + Met \u2192 MK-4618 + Met", "Panel B: MK-4618 + Amlo \u2192 PBO + Amlo", "Panel B: PBO + Amlo \u2192 MK-4618 + Amlo"]}, {"type": "DRUG", "name": "Metoprolol", "description": "Previously prescribed daily dose of open-label metoprolol for the duration of the study", "armGroupLabels": ["Panel A: MK-4618 + Met \u2192 PBO + Met", "Panel A: PBO + Met \u2192 MK-4618 + Met"], "otherNames": ["Toprol-XL"]}, {"type": "DRUG", "name": "Amlodipine", "description": "Previously prescribed daily dose of open-label amlodipine for the duration of the study", "armGroupLabels": ["Panel B: MK-4618 + Amlo \u2192 PBO + Amlo", "Panel B: PBO + Amlo \u2192 MK-4618 + Amlo"], "otherNames": ["Norvasc"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage of Participants With a Clinical or Laboratory Adverse Experience", "description": "An adverse experience was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the sponsor's product is also an adverse experience. The percentage of participants with a clinical or laboratory adverse experience was recorded.", "timeFrame": "Up to 42 days"}, {"measure": "Maximum Change From Baseline in Semi-recumbent and Standing Systolic Blood Pressure: Panel A", "description": "Semi-recumbent and standing systolic blood pressure was measured predose and at intervals up to 24 hours postdose on Day 1 and Day 7. The baseline value is the average of measurements taken in the hour before dosing. Participants were to rest quietly in a semi-recumbent position for at least 10 minutes before each semi-recumbent measurement.", "timeFrame": "Baseline (predose) and up to 24 hours postdose on Day 1 and Day 7"}, {"measure": "Maximum Change From Baseline in Semi-recumbent and Standing Systolic Blood Pressure: Panel B", "description": "Semi-recumbent and standing systolic blood pressure was measured predose and at intervals up to 24 hours postdose on Day 1 and Day 7. The baseline value is the average of measurements taken in the hour before dosing. Participants were to rest quietly in a semi-recumbent position for at least 10 minutes before each semi-recumbent measurement.", "timeFrame": "Baseline (predose) and up to 24 hours postdose on Day 1 and Day 7"}], "secondaryOutcomes": [{"measure": "Steady-state Area Under the Plasma Concentration Versus Time Curve (AUC0-24hr) for MK-4618", "description": "Blood samples were collected on Day 7 predose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours postdose for the determination of plasma MK-4618 concentration. The hypothesis for this outcome is that the steady-state AUC0-24hr for MK-4618 is \\>=0.47 uM\\*hr.", "timeFrame": "Predose and up to 24 hours postdose on Day 7"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female not of childbearing potential\n* Not a nursing mother\n* Must be on stable dose of a beta blocker (Panel A only) or amlodipine (Panel B only) for the treatment of hypertension for at least 6 weeks prior to enrollment. Must take the designated daily dose of metoprolol or amlodipine for the duration of the study\n* In good health other than hypertension\n* Nonsmoker\n* Participant has a resting systolic blood pressure \\<150 and \\>95 mmHg and a diastolic blood pressure \\<95 and \\>75 mmHg at prestudy clinical evaluation\n\nExclusion Criteria:\n\n* Any illness that might confound the results of the study or pose a risk by participation\n* History of orthostatic hypotension (decrease in blood pressure upon standing accompanied by symptoms of lightheadedness or dizziness)\n* History of cancer, excepting certain skin or cervical cancers or cancers that were treated successfully 10 or more years prior to screening\n* Condition for which there is a warning, contraindication, or precaution against the use of extended release metoprolol (Panel A) or amlodipine (Panel B)\n* Consumes excessive amounts of alcohol or caffeine daily\n* Has multiple and/or severe allergies (including latex allergy) or has had an anaphylactic reaction or significant intolerance to drugs or food\n* Uses illicit drugs or has a history of drug abuse", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"availIpds": [{"type": "CSR Synopsis", "url": "http://www.merck.com/clinical-trials/study.html?id=4618-010&kw=4618-010&tab=access"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf", "url": "http://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Panel A: MK-4618 + Met \u2192 PBO + Met", "description": "Once daily oral dose of MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 1 followed by once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of metoprolol (Met) for the duration of the study. A 2-week washout period follows Period 1."}, {"id": "FG001", "title": "Panel A: PBO + Met \u2192 MK-4618 + Met", "description": "Once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 1 followed by MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of metoprolol (Met) for the duration of the study. A 2-week washout period follows Period 1."}, {"id": "FG002", "title": "Panel B: MK-4618 + Amlo \u2192 PBO + Amlo", "description": "Once daily oral dose of MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 1 followed by once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of amlodipine (Amlo) for the duration of the study. A 2-week washout period follows Period 1."}, {"id": "FG003", "title": "Panel B: PBO + Amlo \u2192 MK-4618 + Amlo", "description": "Once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 1 followed by MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of amlodipine (Amlo) for the duration of the study. A 2-week washout period follows Period 1."}], "periods": [{"title": "Treatment Period 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "comment": "The discontinued participant was replaced", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "comment": "The discontinued participant was replaced", "numSubjects": "7"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Discontinued due to blood draws", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}]}, {"title": "Two-week Washout Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}, {"title": "Treatment Period 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Panel A Participants", "description": "Once daily oral dose of MK-4618 (two 50-mg tablets) or placebo (two tablets) on Days 1 through 7 in Period 1 followed by the crossover treatment in Period 2. Participants receive previously prescribed daily dose of metoprolol for the duration of the study. A 2-week washout period follows Period 1."}, {"id": "BG001", "title": "Panel B Participants", "description": "Once daily oral dose of MK-4618 (two 50-mg tablets) or placebo (two tablets) on Days 1 through 7 in Period 1 followed by the crossover treatment in Period 2. Participants receive previously prescribed daily dose of amlodipine for the duration of the study. A 2-week washout period follows Period 1."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "26"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "53.8", "lowerLimit": "42", "upperLimit": "68"}, {"groupId": "BG001", "value": "55.2", "lowerLimit": "41", "upperLimit": "77"}, {"groupId": "BG002", "value": "54.5", "lowerLimit": "41", "upperLimit": "77"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "12"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "14"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage of Participants With a Clinical or Laboratory Adverse Experience", "description": "An adverse experience was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the sponsor's product is also an adverse experience. The percentage of participants with a clinical or laboratory adverse experience was recorded.", "populationDescription": "The All Subjects as Treated population included all participants who received \\>=1 dose of study drug", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to 42 days", "groups": [{"id": "OG000", "title": "Panel A: MK-4618 + Met", "description": "Once daily oral dose of MK-4618 (two 50-mg tablets) in Period 1 or 2. Participants receive previously prescribed daily dose of metoprolol for the duration of the study. A 2-week washout period follows Period 1."}, {"id": "OG001", "title": "Panel A: PBO + Met", "description": "Once daily oral dose of placebo (two tablets) in Period 1 or 2. Participants receive previously prescribed daily dose of metoprolol for the duration of the study. A 2-week washout period follows Period 1."}, {"id": "OG002", "title": "Panel B: MK-4618 + Amlo", "description": "Once daily oral dose of MK-4618 (two 50-mg tablets) in Period 1 or 2. Participants receive previously prescribed daily dose of amlodipine for the duration of the study. A 2-week washout period follows Period 1."}, {"id": "OG003", "title": "Panel B: PBO + Amlo", "description": "Once daily oral dose of placebo (two tablets) in Period 1 or 2. Participants receive previously prescribed daily dose of amlodipine for the duration of the study. A 2-week washout period follows Period 1."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "13"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "33.3"}, {"groupId": "OG001", "value": "53.8"}, {"groupId": "OG002", "value": "41.7"}, {"groupId": "OG003", "value": "61.5"}]}]}]}, {"type": "PRIMARY", "title": "Maximum Change From Baseline in Semi-recumbent and Standing Systolic Blood Pressure: Panel A", "description": "Semi-recumbent and standing systolic blood pressure was measured predose and at intervals up to 24 hours postdose on Day 1 and Day 7. The baseline value is the average of measurements taken in the hour before dosing. Participants were to rest quietly in a semi-recumbent position for at least 10 minutes before each semi-recumbent measurement.", "populationDescription": "The All Subjects as Treated population included all participants who received \\>=1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline (predose) and up to 24 hours postdose on Day 1 and Day 7", "groups": [{"id": "OG000", "title": "Panel A: MK-4618 + Met", "description": "Once daily oral dose of MK-4618 (two 50-mg tablets) in Period 1 or 2. Participants receive previously prescribed daily dose of metoprolol for the duration of the study. A 2-week washout period follows Period 1."}, {"id": "OG001", "title": "Panel A: PBO + Met", "description": "Once daily oral dose of placebo (two tablets) in Period 1 or 2. Participants receive previously prescribed daily dose of metoprolol for the duration of the study. A 2-week washout period follows Period 1."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "13"}]}], "classes": [{"title": "Semi-recumbent, Day 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "16.03", "lowerLimit": "9.46", "upperLimit": "22.61"}, {"groupId": "OG001", "value": "17.25", "lowerLimit": "10.93", "upperLimit": "23.57"}]}]}, {"title": "Semi-recumbent, Day 7", "categories": [{"measurements": [{"groupId": "OG000", "value": "14.38", "lowerLimit": "7.81", "upperLimit": "20.96"}, {"groupId": "OG001", "value": "12.10", "lowerLimit": "5.78", "upperLimit": "18.42"}]}]}, {"title": "Standing, Day 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "14.79", "lowerLimit": "7.43", "upperLimit": "22.15"}, {"groupId": "OG001", "value": "13.14", "lowerLimit": "6.01", "upperLimit": "20.26"}]}]}, {"title": "Standing, Day 7", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.12", "lowerLimit": "-1.24", "upperLimit": "13.49"}, {"groupId": "OG001", "value": "7.21", "lowerLimit": "0.09", "upperLimit": "14.34"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Semi-recumbent, Day 1", "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Hypothesis: the upper bound of the 90% confidence interval for the difference in maximum change from baseline for MK-4618 + Met versus PBO + Met is \\<20 mmHg", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.22", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.42", "ciUpperLimit": "5.98", "estimateComment": "The estimated parameter is mean maximum change from baseline for placebo minus MK-4618. Mean and confidence interval for the difference were obtained from linear mixed effects model performed on the maximum increase from baseline values."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Semi-recumbent, Day 7", "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Hypothesis: the upper bound of the 90% confidence interval for the difference in maximum change from baseline for MK-4618 + Met versus PBO + Met is \\<20 mmHg", "paramType": "Mean Difference (Final Values)", "paramValue": "2.29", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.92", "ciUpperLimit": "9.49", "estimateComment": "The estimated parameter is mean maximum change from baseline for placebo minus MK-4618. Mean and confidence interval for the difference were obtained from linear mixed effects model performed on the maximum increase from baseline values."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Standing, Day 1", "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Hypothesis: the upper bound of the 90% confidence interval for the difference in maximum change from baseline for MK-4618 + Met versus PBO + Met is \\<20 mmHg", "paramType": "Mean Difference (Final Values)", "paramValue": "1.65", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.31", "ciUpperLimit": "8.62", "estimateComment": "The estimated parameter is mean maximum change from baseline for placebo minus MK-4618. Mean and confidence interval for the difference were obtained from linear mixed effects model performed on the maximum increase from baseline values."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Standing, Day 7", "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Hypothesis: the upper bound of the 90% confidence interval for the difference in maximum change from baseline for MK-4618 + Met versus PBO + Met is \\<20 mmHg", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.09", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.06", "ciUpperLimit": "5.88", "estimateComment": "The estimated parameter is mean maximum change from baseline for placebo minus MK-4618. Mean and confidence interval for the difference were obtained from linear mixed effects model performed on the maximum increase from baseline values."}]}, {"type": "PRIMARY", "title": "Maximum Change From Baseline in Semi-recumbent and Standing Systolic Blood Pressure: Panel B", "description": "Semi-recumbent and standing systolic blood pressure was measured predose and at intervals up to 24 hours postdose on Day 1 and Day 7. The baseline value is the average of measurements taken in the hour before dosing. Participants were to rest quietly in a semi-recumbent position for at least 10 minutes before each semi-recumbent measurement.", "populationDescription": "The All Subjects as Treated population included all participants who received \\>=1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline (predose) and up to 24 hours postdose on Day 1 and Day 7", "groups": [{"id": "OG000", "title": "Panel B: MK-4618 + Amlo", "description": "Once daily oral dose of MK-4618 (two 50-mg tablets) in Period 1 or 2. Participants receive previously prescribed daily dose of amlodipine for the duration of the study. A 2-week washout period follows Period 1."}, {"id": "OG001", "title": "Panel B: PBO + Amlo", "description": "Once daily oral dose of placebo (two tablets) in Period 1 or 2. Participants receive previously prescribed daily dose of amlodipine for the duration of the study. A 2-week washout period follows Period 1."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "13"}]}], "classes": [{"title": "Semi-recumbent, Day 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "14.69", "lowerLimit": "9.65", "upperLimit": "19.72"}, {"groupId": "OG001", "value": "12.74", "lowerLimit": "7.87", "upperLimit": "17.61"}]}]}, {"title": "Semi-recumbent, Day 7", "categories": [{"measurements": [{"groupId": "OG000", "value": "10.52", "lowerLimit": "5.48", "upperLimit": "15.55"}, {"groupId": "OG001", "value": "16.43", "lowerLimit": "11.56", "upperLimit": "21.30"}]}]}, {"title": "Standing, Day 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.50", "lowerLimit": "1.27", "upperLimit": "11.73"}, {"groupId": "OG001", "value": "12.75", "lowerLimit": "7.70", "upperLimit": "17.79"}]}]}, {"title": "Standing, Day 7", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.33", "lowerLimit": "1.10", "upperLimit": "11.57"}, {"groupId": "OG001", "value": "7.90", "lowerLimit": "2.85", "upperLimit": "12.95"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Semi-recumbent, Day 1", "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Hypothesis: the upper bound of the 90% confidence interval for the difference in maximum change from baseline for MK-4618 + Amlo versus PBO + Amlo is \\<20 mmHg", "paramType": "Mean Difference (Final Values)", "paramValue": "1.95", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.85", "ciUpperLimit": "6.75", "estimateComment": "The estimated parameter is mean maximum change from baseline for placebo minus MK-4618. Mean and confidence interval for the difference were obtained from linear mixed effects model performed on the maximum increase from baseline values."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Semi-recumbent, Day 7", "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Hypothesis: the upper bound of the 90% confidence interval for the difference in maximum change from baseline for MK-4618 + Amlo versus PBO + Amlo is \\<20 mmHg", "paramType": "Mean Difference (Final Values)", "paramValue": "-5.91", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.71", "ciUpperLimit": "-1.11", "estimateComment": "The estimated parameter is mean maximum change from baseline for placebo minus MK-4618. Mean and confidence interval for the difference were obtained from linear mixed effects model performed on the maximum increase from baseline values."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Standing, Day 1", "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Hypothesis: the upper bound of the 90% confidence interval for the difference in maximum change from baseline for MK-4618 + Amlo versus PBO + Amlo is \\<20 mmHg", "paramType": "Mean Difference (Final Values)", "paramValue": "-6.25", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-11.47", "ciUpperLimit": "-1.03", "estimateComment": "The estimated parameter is mean maximum change from baseline for placebo minus MK-4618. Mean and confidence interval for the difference were obtained from linear mixed effects model performed on the maximum increase from baseline values."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Standing, Day 7", "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Hypothesis: the upper bound of the 90% confidence interval for the difference in maximum change from baseline for MK-4618 + Amlo versus PBO + Amlo is \\<20 mmHg", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.57", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.79", "ciUpperLimit": "3.65", "estimateComment": "The estimated parameter is mean maximum change from baseline for placebo minus MK-4618. Mean and confidence interval for the difference were obtained from linear mixed effects model performed on the maximum increase from baseline values."}]}, {"type": "SECONDARY", "title": "Steady-state Area Under the Plasma Concentration Versus Time Curve (AUC0-24hr) for MK-4618", "description": "Blood samples were collected on Day 7 predose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours postdose for the determination of plasma MK-4618 concentration. The hypothesis for this outcome is that the steady-state AUC0-24hr for MK-4618 is \\>=0.47 uM\\*hr.", "populationDescription": "The Per Protocol population included participants who complied with the protocol sufficiently to ensure that the data will likely exhibit the effects of treatment, according to the underlying scientific model.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "uM*hr", "timeFrame": "Predose and up to 24 hours postdose on Day 7", "groups": [{"id": "OG000", "title": "Panel A: MK-4618 + Met", "description": "Once daily oral dose of MK-4618 (two 50-mg tablets) in Period 1 or 2. Participants receive previously prescribed daily dose of metoprolol for the duration of the study. A 2-week washout period follows Period 1."}, {"id": "OG001", "title": "Panel B: MK-4618 + Amlo", "description": "Once daily oral dose of MK-4618 (two 50-mg tablets) in Period 1 or 2. Participants receive previously prescribed daily dose of amlodipine for the duration of the study. A 2-week washout period follows Period 1."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.60", "lowerLimit": "2.09", "upperLimit": "3.24"}, {"groupId": "OG001", "value": "4.60", "lowerLimit": "3.69", "upperLimit": "5.74"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Up to 42 days", "eventGroups": [{"id": "EG000", "title": "Panel A: MK-4618 + Met", "description": "Once daily oral dose of MK-4618 (two 50-mg tablets) in Period 1 or 2. Participants receive previously prescribed daily dose of metoprolol for the duration of the study. A 2-week washout period follows Period 1.", "seriousNumAffected": 0, "seriousNumAtRisk": 12, "otherNumAffected": 4, "otherNumAtRisk": 12}, {"id": "EG001", "title": "Panel A: PBO + Met", "description": "Once daily oral dose of placebo (two tablets) in Period 1 or 2. Participants receive previously prescribed daily dose of metoprolol for the duration of the study. A 2-week washout period follows Period 1.", "seriousNumAffected": 0, "seriousNumAtRisk": 13, "otherNumAffected": 7, "otherNumAtRisk": 13}, {"id": "EG002", "title": "Panel B: MK-4618 + Amlo", "description": "Once daily oral dose of MK-4618 (two 50-mg tablets) in Period 1 or 2. Participants receive previously prescribed daily dose of amlodipine for the duration of the study. A 2-week washout period follows Period 1.", "seriousNumAffected": 0, "seriousNumAtRisk": 12, "otherNumAffected": 5, "otherNumAtRisk": 12}, {"id": "EG003", "title": "Panel B: PBO + Amlo", "description": "Once daily oral dose of placebo (two tablets) in Period 1 or 2. Participants receive previously prescribed daily dose of amlodipine for the duration of the study. A 2-week washout period follows Period 1.", "seriousNumAffected": 0, "seriousNumAtRisk": 13, "otherNumAffected": 8, "otherNumAtRisk": 13}], "otherEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA version 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "Abdominal pain lower", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA version 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA version 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "Application site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA version 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "Application site rash", "organSystem": "General disorders", "sourceVocabulary": "MedDRA version 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA version 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA version 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}, {"term": "Vessel puncture site swelling", "organSystem": "General disorders", "sourceVocabulary": "MedDRA version 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA version 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}, {"term": "Weight increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA version 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA version 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA version 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA version 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA version 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 6, "numAffected": 5, "numAtRisk": 13}, {"groupId": "EG002", "numEvents": 4, "numAffected": 2, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 13}]}, {"term": "Depressed mood", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA version 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}, {"term": "Dysuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA version 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "Penile pain", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA version 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA version 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}, {"term": "Nasal congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA version 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA version 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "Flushing", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA version 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}, {"term": "Hot flush", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA version 15.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 13}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission"}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme, Corp.", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01", "removedCountries": ["United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008790", "term": "Metoprolol"}, {"id": "D000017311", "term": "Amlodipine"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000013565", "term": "Sympatholytics"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000058671", "term": "Adrenergic beta-1 Receptor Antagonists"}, {"id": "D000000319", "term": "Adrenergic beta-Antagonists"}, {"id": "D000018674", "term": "Adrenergic Antagonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M11762", "name": "Metoprolol", "asFound": "Neonatal", "relevance": "HIGH"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M16344", "name": "Sympatholytics", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M29197", "name": "Adrenergic beta-1 Receptor Antagonists", "relevance": "LOW"}, {"id": "M3671", "name": "Adrenergic beta-Antagonists", "relevance": "LOW"}, {"id": "M20755", "name": "Adrenergic Antagonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}]}}, "hasResults": true}